APRIL

By Targets:	SARS-CoV (1) TNF Receptor (1)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P990070

Zigakibart BION-1301	TNF Receptor	Inflammation/Immunology
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library	457 compounds
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 457 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Autoimmune Disease Compound Library

457 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 457 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Target	Research Area

HY-P99901

Sibeprenlimab VIS649	Inhibitory Antibodies	Cancer
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit *APRIL*. Sibeprenlimab can be used for the research of IgA nephropathy (IgAN) .

HY-P99568

Telitacicept RC18	Inhibitory Antibodies	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator *(BLyS)/APRIL* (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P990070

Zigakibart BION-1301	TNF Receptor	Inflammation/Immunology
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

Species:	Human (3) Mouse (2) Cynomolgus (1)
Tag:	His (4) Tag Free (1) Avi (2) Fc (1) Flag (3)
Source:	HEK293 (4) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7538

	APRIL/TNFSF13 Protein, Mouse (HEK293, Fc) rMuAPRIL/TNFSF13, N-Fc; CD256; TALL2; APRIL; TNFSF13	Mouse	HEK293
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. Mouse APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. APRIL/TNFSF13 Protein, Mouse (HEK293, Fc) is produced by HEK293 cells (A96-K240) with N-terminal Fc-tag.

HY-P70733

	APRIL/TNFSF13 Trimer Protein, Human (HEK293, Flag-His) Tumor necrosis factor ligand superfamily member 13; A proliferation-inducing ligand; APRIL; TNF- and APOL-related leukocyte expressed ligand 2; TALL-2; TNF-related death ligand 1; TRDL-1; CD256; TNFSF13	Human	HEK293
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. Human APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. APRIL/TNFSF13 Protein, Human (HEK293, Flag-His) is produced by HEK293 cells (K112-L250) with N-terminal His- and Flag-tags.

HY-P77564

	APRIL/TNFSF13 Protein, Cynomolgus (HEK293, His-Flag-Avi) CD256; TALL2; TALL-2; TNFSF13; APRIL; APRILFLJ57090; TRDL1; TRDL-1; ZTNF2; 2310026N09Rik	Cynomolgus	HEK293
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. APRIL/TNFSF13 Protein, Cynomolgus (HEK293, His-Flag-Avi) is produced by HEK293 cells (K112-L250) with N-terminal His-, Avi-, and Flag-tags.

HY-P700661

	APRIL/TNFSF13 Protein, Human (Biotinylated, HEK293, Flag, His-Avi) CD256; TALL2; TALL-2; TNFSF13; APRIL; APRILFLJ57090; TRDL1; TRDL-1; ZTNF2; 2310026N09Rik	Human	HEK293
	APRIL/TNFSF13 is a TNF superfamily cytokine that affects tumor cell growth by binding to TNFRSF13B/TACI and TNFRSF17/BCMA receptors. Its homotrimeric structure highlights a potential role in oncogenic processes and immune functions involving monocytes and macrophages. APRIL/TNFSF13 Protein, Human (Biotinylated, HEK293, Flag, His-Avi) is the recombinant human-derived APRIL/TNFSF13 protein, expressed by HEK293 , with N-Flag, C-Avi, N-His labeled tag. The total length of APRIL/TNFSF13 Protein, Human (Biotinylated, HEK293, Flag, His-Avi) is 139 a.a., with molecular weight of 55-65 kDa.

HY-P7320

	APRIL/TNFSF13 Protein, Mouse rMuAPRIL/TNFSF13; TNFSF 13; TNFSF-13; CD256	Mouse	E. coli
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. Mouse APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. APRIL/TNFSF13 Protein, Mouse is produced by E. coli (R50-L241) with length of 192 amino acids.

HY-P700016AF

	*Animal-Free APRIL/TNFSF13 Protein, Human (His)* TNFSF13; CD256; TALL-2; TALL2; TNLG7B; TRDL-1; UNQ383/PRO715; ZTNF2	Human	E. coli
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. Human APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. Animal-Free APRIL/TNFSF13 Protein, Human (His) is produced by E. coli (A105-L250) with C-terminal His-tag.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P82513

APRIL Antibody (YA2258)

APRIL; CD256; TALL2; TNFSF13; TRDL1; ZTNF2
WB, ICC/IF Human, Mouse, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.